Tag Archives: immuno biotech

Autism is Eradicated in 15% of Cases with GcMAF in a trial of 1,500 Children

Over the last two years, four doctors led by Dr Jeffrey Bradstreet have eradicated autism using GcMAF in 15% of children and improved 70%. Another 15% did not respond.

St Peter Port, Guernsey (April 3, 2013) — Yesterday, April 2, was World Autism Awareness Day. Over the last two years, four doctors led by Dr Jeffrey Bradstreet have eradicated autism using GcMAF in 15% of children and improved 70%. Another 15% did not respond.

GcMAF is a vital part of the human immune system that does not function without it. However, many viruses attempt to prevent production of the body’s own GcMAF. If successful, this collapses the immune system, resulting in the infections growing unchecked. Immuno Biotech extracts and isolates GcMAF molecules that can then be injected to restore the body’s level of GcMAF to normal so that it can fight infections naturally. The quality of Immuno Biotech’s GcMAF and their exhaustive testing has made it the World’s leading supplier and the provider of choice for doctors and scientists with the company being cited in eleven research papers to date.

David Noakes, Immuno Biotech’s CEO, explained, “Dr Bradstreet used the nagalase and other tests to prove that 85% of autistic children had high levels of viruses and a compromised immune system. He did a study of 1500 autistic children and gave them weekly injections of our GcMAF. 70% of the children responded to the treatment with reduced symptoms, and an another 15% made full recoveries. Further trials around the world are coming up with identical results. The reduction of autistic symptoms is permanent provided that GcMAF has been taken for long enough for the body to start to produce its own GcMAF at normal levels, typically 24 weeks, but first results are usually seen inside 8 weeks.”

Dr. Jeff Bradstreet MD is an internationally recognized researcher in autism (http://www.drbradstreet.org) and will be presenting his latest finding on the effects of GcMAF on autism at the world’s first GcMAF conference, which will be held on the 19th, 20th and 21st of April in Frankfurt, Germany. Presentations by leading scientists and doctors from around the world will report on their exceptional results with case histories. Details can be found at http://gcmafconference.org/. Currently there are over 60 research papers on GcMAF by 142 eminent scientists with new peer-reviewed papers being added at an increasing rate from university teams and doctors from dozens of countries. Many of the independent research papers on GcMAF are listed on http://www.gcmaf.eu.

Background
A weekly injection of a tiny clear drop restores the level of GcMAF to normal, effectively one millionth of a blood transfusion. That enables the body’s own immune system to fight the disease, with the only occasional side effects being mild, cold-like symptoms as the immune system wakes up. The time it takes to fight the infection and return to producing normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.

Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Tel: 0044 7781 411737, Web: http://www.gcmaf.eu and click “contact” at the top to email.

Immuno Biotech to present third paper on GcMAF at Immunotherapy and Immunomonitoring Conference

GcMAF helps body destroy cancer cells.

St Peter Port, Guernsey (March 4, 2013) — Immuno Biotech Ltd has been invited to present its latest research paper on GcMAF at the 3rd Immunotherapy and Immunomonitoring Conference on April 22-25, 2013 in Krakow, Poland. Entitled “The effects of Vitamin D-binding protein-derived macrophage activating factor (GcMAF) on human breast cancer and neuroblastoma cells,” it is about examining how GcMAF destroys breast and brain cancer cells by use of microscope photography and the fixing and staining of microscope slides. GcMAF is a key part of the human body’s immune system and the body’s own production is often reduced or prevented by diseases and cancer.

“This is the third scientific paper that we have presented in two months,” said David Noakes, the CEO of Immuno Biotech. “We are actively adding to the growing body of scientific papers being generated by leading scientists around the world who are investigating how GcMAF can help the body naturally fight off diseases and cancer. Currently there are over 59 research papers on GcMAF by 142 eminent scientists. This growing interest in GcMAF by the scientific community resulted in this invitation to present our latest scientific paper at this prestigious conference. Having positive peer reviews at these international conferences on the effects of GcMAF is stimulating more scientists to start looking at how GcMAF can help in their research into diseases and cancer.”

In the past two months, Immuno Biotech has presented at the International Cancer Conference in Dubai and, as a result, was asked to supply GcMAF for testing by the University of Sharjah on its library of 2,000 cancer cell lines. The same paper was also presented at the Immunology Conference in San Diego and was so well received that a number of scientists said that they would be now be re-directing their work. And at the International Dubai Autism Conference, their paper on GcMAF and autism, and the trial on 1,500 children with 15% of children making full recoveries, and 85% improving, resulted in Immuno Biotech being asked to supply GcMAF for similar large scale trials in Dubai.

“We are investing heavily in state-of-the-art research equipment and intend to produce several more papers by the end of the year,” added David Noakes. “For example, our new high powered microscopes have been able to video GcMAF being used to destroy cancer cells by activating the macrophages, which are the body’s own natural way of fighting invaders and cancer. We are the first to have videoed this and it really impresses the audiences at the conferences to see GcMAF actually in action.” Video at http://www.youtube.com/watch?v=D1WZrnCcH24&feature=player_embedded.

Immuno Biotech is organising the World’s first GcMAF Immunology Conference that will be held at the Holiday Inn Frankfurt, Germany on 19th, 20th and 21st of April. Registration is open now for doctors and research scientists at http://gcmafconference.org and, from March 20th, registration opens for members of the public and patients wishing to learn more about GcMAF.

The quality of Immuno Biotech’s GcMAF has made it the World’s leading supplier and the provider of choice for scientists with the company being cited in over eight research papers to date. Many of the independent research papers on GcMAF are listed on its website http://www.gcmaf.eu.

Background
GcMAF is continually produced by healthy humans and is a vital part of the body’s immune system. It directs the immune system to destroy foreign invaders, such as viruses and bacteria, as well as the body’s own cells when they turn cancerous. However, many diseases attempt to prevent production of the body’s own GcMAF and, if successful, that prevents the immune system from fighting them resulting in the diseases growing unchecked and becoming chronic.

Immuno Biotech extracts GcMAF molecules from healthy human blood. A weekly injection of a tiny clear drop restores the level of GcMAF to normal – effectively a millionth of a conventional transfusion. This enables the body’s own natural defence mechanisms to fight the infection with the only occasional side effects being mild, cold-like symptoms as the immune system starts to function normally. It is extremely safe as it is a naturally occurring blood product. Noticeable improvements usually happen within three weeks and the time it takes for the body to fight the infection and return to being able to produce normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000 – a fraction of the cost of chemotherapy, and, according to the research papers, more effective at fighting cancer. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.

Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Ph: 0044 7781 411737, Website: http://www.gcmaf.eu and click “contact” at the top to email.

Immuno Biotech organises world’s first GcMAF Immunology Conference

The conference will have talks by leading scientists and doctors from around the world and feature new research papers on the uses of GcMAF to restore the body’s immune system to full strength to fight diseases, autism and cancer.

St Peter Port, Guernsey (February 26, 2013) — The world’s first GcMAF conference will be held on the 19th, 20th and 21st of April in the attractive woodland Conference Centre at the Holiday Inn Frankfurt, Germany. Sponsored by Immuno Biotech Ltd, the conference will have talks by leading scientists and doctors from around the world and feature new research papers on the uses of GcMAF to restore the body’s immune system to full strength to fight diseases, autism and cancer.

David Noakes, Immuno Biotech’s CEO, said, “When research scientists and doctors meet to add together their individual results into one whole, the science takes a great step forward. It’s a pooling of the latest discoveries. We expect to come up with a definitive list of synergistic treatments which will allow doctors to treat stage 3 and some stage 4 cancers with the same 80% success that they achieve with GcMAF alone on stage 2 cancers.

“At the moment GcMAF eradicates autism in 15% of cases. By identifying the best complimentary treatments we hope to take that up to 40%. Amongst others, we hope to take ME/CFS from 30 to 50% success. The workshops will encourage informal networking and new ideas. We have a packed programme of talks by leading GcMAF researchers, doctors reporting on their success at eradicating cancer, autism and ME/CFS with GcMAF and, as a result, registrations are already flooding in.”

Registration is open now for doctors and research scientists at http://gcmafconference.org and, from March 20th, registration opens for members of the public and patients wishing to learn more about GcMAF.

Immuno Biotech extracts and isolates GcMAF molecules from healthy human blood. As part of the process of tests and assays to ensure its GcMAF is active, it has been conducting laboratory research into the methods by which GcMAF destroys cancers cells, and is publishing its first three research papers at international conferences on cancer, immunology and autism. Currently there are over 60 research papers on GcMAF by 142 eminent scientists with new peer-reviewed papers being added at an increasing rate from university teams and doctors from dozens of countries.

The quality of Immuno Biotech’s GcMAF has made it the World’s leading supplier and the provider of choice for doctors and scientists with the company being cited in eleven research papers to date. Many of the independent research papers on GcMAF are listed on its website http://www.gcmaf.eu.

Background
GcMAF is a vital part of the human immune system, which doesn’t work without it. However, many diseases including cancer attempt to prevent production of the body’s own GcMAF and, if successful, that prevents the immune system from fighting them, resulting in the diseases growing unchecked and becoming chronic.

Immuno Biotech extracts GcMAF molecules from healthy blood. A weekly injection of a tiny clear drop restores the level of GcMAF in the blood to normal, effectively one millionth of a blood transfusion. That enables the body’s own immune system to fight the disease, with the only occasional side effects being mild, cold-like symptoms as the immune system starts to function normally. The time it takes for the body to fight the infection and return to being able to produce normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000 – a fraction of the cost of conventional treatments. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.

Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Ph: 0044 7781 411737, Website: http://www.gcmaf.eu and click “contact” at the top to email.

Immuno Biotech presents GcMAF Research Papers on fighting Cancer and Autism treatment at International Conferences in the USA and Dubai

GcMAF helps fight Autism and Cancer by rebuilding body’s immune system.

Guernsey, UK (February 8, 2013) — On February 1, 2013, in simultaneous presentations at the Immunology Conference in San Diego, California and at the International Cancer Conference at the University of Sharjah in the United Arab Emirates, Guernsey-based company, Immuno Biotech Ltd. presented its latest research paper on GcMAF. The presentation was entitled “Multifaceted immunotherapeutic effects of GcMAF on human breast cancer cells.”

It included videos, taken through high powered microscopes in their laboratory, showing cancer cells being destroyed using GcMAF molecules, which they had extracted from human blood. GcMAF is a key part of the human body’s immune system and the body’s own production is often reduced as part of the attacking mechanism of diseases and cancer.

Lynda Thyer presented to an audience of over 200 American scientists at the Immunology Conference and was congratulated on the content by other scientists afterwards, in particular the videos which are a world first.

David Noakes, the CEO of Immuno Biotech, presented at the International Cancer Conference and was told afterwards that his presentation was the most easily understood in the three days of the conference. The University was sufficiently impressed to ask Immuno Biotech to provide GcMAF for use with the University’s huge library of 2,000 cancer cell lines, so that GcMAF can be tested with many more types of cancers in the laboratory. This will extend the knowledge of the effectiveness of GcMAF which has mainly been used in human trials so far. The University of Sharjah is one of the world leaders in cancer and molecular research, with state-of-the-art facilities attracting resident professors from all over the world.

David Noakes will also be presenting Immuno Biotech’s “GcMAF in Autism” research paper at the International Dubai Autism Conference, which was based on a US trial with 1500 autistic children. Most of them had significant reductions in autistic symptoms indicating that infection is playing a role in some forms of autism. The company has already been asked to supply GcMAF for three Dubai autism trials, on top of the 1,500 autistic children already treated. The conference will be held from February 6-9, 2013 at Zayed University, Dubai, bringing together international certified experts in the fields of behavioural therapy and special education.

There are 59 research papers by 142 eminent scientists on GcMAF, and Immuno Biotech Ltd are immensely proud to be adding their first two research papers to the list, with plans for lab experiments and human trial results data for at least another six papers this year.

David Noakes, Immuno Biotech’s CEO, said, “Isolating GcMAF is a complex process. Many scientists find it very challenging and time consuming and often fail to isolate it correctly and so they come to us as a source of consistent quality for their research. We have perfected our process in a state-of-the-art laboratory in the UK that isolates GcMAF from human blood and makes it available in a pure, sterile form to scientists, doctors, patients and researchers around the World. We are continually delighted by the flood of positive results in scientific papers that state GcMAF helps fight an increasingly wide range of diseases.”

The quality of Immuno Biotech’s GcMAF has made it the World’s leading supplier and the provider of choice for scientists with the company being cited in over eight research papers to date. Many of the independent research papers on GcMAF are listed on its website http://www.gcmaf.eu.

Background
GcMAF is continually produced by healthy humans and is a vital part of the body’s immune system. It directs the immune system to destroy foreign invaders, such as viruses and bacteria, as well as the body’s own cells when they turn cancerous. However, many diseases attempt to prevent production of the body’s own GcMAF and, if successful, that prevents the immune system from fighting them resulting in the diseases growing unchecked and becoming chronic.

Immuno Biotech has perfected the technique of extracting and isolating GcMAF molecules from healthy human blood. A weekly injection of a tiny clear drop restores the level of GcMAF in the blood to normal and enables the body’s own natural defence mechanisms to fight the infection with the only occasional side effects being mild, cold-like symptoms as the immune system starts to function normally. Noticeable improvements usually happen within three weeks and the time it takes for the body to fight the infection and return to being able to produce normal levels of its own GcMAF depends on the severity of the infection or cancer. An eight week course costs €660 including shipping so a typical 24 week course costs under €2000 – a fraction of the cost of chemotherapy, and according to the research papers, more effective at fighting cancer. Immuno Biotech has supplied 4,000 patients through 300 doctors in 30 nations.

Immuno Biotech Contact: Beate Keisa, Immuno Biotech Ltd., Tel: 0044 7781 411737, Web: http://gcmaf.eu and click “contact” at the top to email.